International Assets Investment Management LLC Purchases New Position in DexCom, Inc. (NASDAQ:DXCM)

International Assets Investment Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,008 shares of the medical device company’s stock, valued at approximately $1,986,000.

Other institutional investors have also bought and sold shares of the company. Bartlett & CO. Wealth Management LLC acquired a new stake in DexCom in the 4th quarter valued at $27,000. Harbour Investments Inc. boosted its stake in DexCom by 55.6% in the third quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock worth $31,000 after purchasing an additional 120 shares in the last quarter. Atlas Capital Advisors LLC acquired a new position in DexCom in the second quarter worth $33,000. Washington Trust Advisors Inc. boosted its stake in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares in the last quarter. Finally, NBC Securities Inc. acquired a new position in DexCom in the third quarter worth $47,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on DXCM. Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Raymond James boosted their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.40.

DexCom Trading Down 2.7 %

NASDAQ DXCM opened at $130.71 on Friday. The stock has a 50-day simple moving average of $129.55 and a 200 day simple moving average of $116.66. The company has a market capitalization of $50.39 billion, a PE ratio of 99.78, a P/E/G ratio of 2.30 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm’s revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 earnings per share. Research analysts forecast that DexCom, Inc. will post 1.76 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.